ArticleNoro psikiyatri arsivi2026
Noninvasive Assessment Follow-Up of Progress in MS Patients.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple sclerosis (MS) is the leading cause of disability in young adults. We aimed to monitor disease progression characteristics using cognitive and physical parameters with optical coherence tomography (OCT) and Magnetic Resonance Spectroscopy (MRS). Methods: Fifteen relapsing remitting (RRMS), thirteen secondary progressive (SPMS) and twelve primary progressive (PPMS) patients were included. The Expanded Disability Status Scale (EDSS), Nine-Hole Peg Test (9 HPT), Timed 25-Foot Walk Test (T25FWT), Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), Montreal Cognitive Assessment (MoCA), MRS and OCT examinations were performed at baseline and follow-up. Results: EDSS, Beck Depression Scale scores, 9-HPT and T25FWT duration scores were higher in the PPMS group compared to the other groups, whereas MoCA, SDMT, CVLT2, and BVMT-R scores were the lowest in this group. Retinal nerve fiber layer (RNFL) measurements in the right (p=0.023) and left (p=0.028) nasal quadrants were found to be higher in the RRMS group compared to the progressive groups. Baseline MRS showed a lower Thalamus myoinositol/creatinine (mI/Cr) ratio in progressed patients compared to stable patients (p=0.003). A cut-off value of baseline Thalamus mI/Cr ratio <0.066 for predicting disease progression based on baseline Thalamus mI/Cr was determined to be <0.066, with an 81.82% sensitivity, and 79.17% specificity, 64.29% positive predictive value (PPV), and 90.48% negative predictive value (NPV) (p=0.003). Conclusion: Early detection of disease progression has critical importance for MS. Besides prognostic serum or cerebrospinal fluid biomarker tests, noninvasive methods such as disability scales and/or imaging techniques may have a significant impact and are easily replicable. As an advanced imaging technique, MRS has the potential for ongoing tissue inflammation. In parallel with that, we have obtained a cut-off thalamic mI/Cr ratio value as a significant predictor of disease progression in MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.